As of 2024-12-13, the Fair Value of Xbrane Biopharma AB (XBRANE.ST) is -1.21 SEK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.17 SEK, the upside of Xbrane Biopharma AB is -800.22%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 5Y Avg | |
| Net income | -187.99 | -226.03 | -188.38 | -172.51 | -388.17 | -232.62 |
| YoY growth | -1,320.29% | -20.23% | 16.66% | 8.42% | -125.01% | -288.09% |
| Market Cap (mil) | 264.60 |
| P/E | |
| Forward P/E |
| EPS | -0.24 |
| Avg earnings growth rate | -288.09% |
| TTM earnings | -370.56 |